3EW

5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide

Created:2014-08-04
Last modified:  2021-03-12

Help

Find related ligands:

Chemical Details

Formal Charge0
Atom Count42
Chiral Atom Count0
Bond Count44
Aromatic Bond Count16
2D diagram of 3EW
Toggle HydrogenToggle Labels

Chemical Component Summary

Name5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide
SynonymsSelumetinib
Systematic Name (OpenEye OEToolkits)6-[(4-bromanyl-2-chloranyl-phenyl)amino]-7-fluoranyl-N-(2-hydroxyethyloxy)-3-methyl-benzimidazole-5-carboxamide
FormulaC17 H15 Br Cl F N4 O3
Molecular Weight457.681
TypeNON-POLYMER

Chemical Descriptors

TypeProgramVersionDescriptor
SMILESACDLabs12.01Brc1ccc(c(Cl)c1)Nc2c(F)c3ncn(c3cc2C(=O)NOCCO)C
SMILESCACTVS3.385Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO
SMILESOpenEye OEToolkits1.9.2Cn1cnc2c1cc(c(c2F)Nc3ccc(cc3Cl)Br)C(=O)NOCCO
Canonical SMILESCACTVS3.385 Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO
Canonical SMILESOpenEye OEToolkits1.9.2 Cn1cnc2c1cc(c(c2F)Nc3ccc(cc3Cl)Br)C(=O)NOCCO
InChIInChI1.03 InChI=1S/C17H15BrClFN4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)
InChIKeyInChI1.03 CYOHGALHFOKKQC-UHFFFAOYSA-N

Drug Info: DrugBank

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
DrugBank IDDB11689 
NameSelumetinib
Groups
  • investigational
  • approved
DescriptionActivation of the Raf-MEK-ERK signalling pathway is known to be implemented in several types of malignancies; thus, mitogen-activated protein kinase kinase (MEK) inhibitors such as selumetinib are important tools that can target the problematic overactivity of this pathway.[A193611] Results from clinical trials investigating earlier developed MEK inhibitors were underwhelming.[A193611] However, selumetinib demonstrated impressive efficacy and tolerability in Phase I trials, leading to its continued investigation for the treatment of various types of tumours in Phase II trials.[A193611] "The novel MEK 1/2 inhibitor, selumetinib, was initially approved solely for the treatment of pediatric patients with Neurofibromatosis type 1 (NF-1) and symptomatic, inoperable plexiform neurofibromas (PN). NF-1 is considered rare, with an estimated incidence of 1/3000 individuals.[A193608] It is a genetic, autosomal dominant condition resulting from mutations of the NF1 gene, which can lead to various complications, including the development of multiple tumours in the nervous system.[A193533,A193608] While some patients with this disorder develop PNs, this is considered relatively uncommon compared to other variants of NF-1.[A193608] Use of selumetinib in this population has shown efficacy in shrinking associated tumours and is linked to other positive clinical outcomes.[A193533] Following its initial FDA approval on April 10, 2020,[L49991] and Health Canada approval on August 23, 2022,[L49986] the regulatory landscape has evolved. Most recently, on November 20, 2025, the FDA expanded this indication to include adults [L53881]
Synonyms
  • Sélumétinib
  • Selumetinib
  • Selumetinib sulfate
  • Selumetinibum
Brand NamesKoselugo
IndicationSelumetinib is indicated for the treatment of neurofibromatosis type 1 (NF1) in adult and pediatric patients one year of age and older who have symptomatic, inoperable plexiform neurofibromas (PN).[A193611,L12852,L12969,L49986,L53881]
Categories
  • Antineoplastic Agents
  • Antineoplastic and Immunomodulating Agents
  • BCRP/ABCG2 Substrates
  • Cytochrome P-450 CYP1A2 Substrates
  • Cytochrome P-450 CYP2C19 Substrates
ATC-CodeL01EE04
CAS number606143-52-6

Drug Targets

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
NameTarget SequencePharmacological ActionActions
Dual specificity mitogen-activated protein kinase kinase 1MPKKKPTPIQLNPAPDGSAVNGTSSAETNLEALQKKLEELELDEQQRKRL...unknowninhibitor
Dual specificity mitogen-activated protein kinase kinase 2MLARRKPVLPALTINPTIAEGPSPTSEGASEANLVDLQKKLEELELDEQQ...unknowninhibitor
Cytochrome P450 2C19MDPFVVLVLCLSCLLLLSIWRQSSGRGKLPPGPTPLPVIGNILQIDIKDV...unknownsubstrate
Cytochrome P450 3A4MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI...unknownsubstrate
Cytochrome P450 2C9MDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDI...unknownsubstrate
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
Pharos CHEMBL1614701
PubChem 10127622
ChEMBL CHEMBL1614701
ChEBI CHEBI:90227